We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Featured
-
-
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
European Medicines Agency approves first two pegfilgrastim biosimilars and another adalimumab biosimilar Pfizer launches NivestymTM,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 8, 2018, Amgen Inc. (“Amgen”) filed suit against Adello Biologics, LLC (“Adello”) in the District of New Jersey, alleging...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we recently covered, May 15, 2018, saw the FDA granting approval to Hospira (now a Pfizer subsidiary) for its Retacrit injection, a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
This article provides an update on our prior analysis of the infliximab litigation involving Janssen Biotech, Inc. (“Janssen”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]